Georgia State University

ScholarWorks @ Georgia State University
Respiratory Therapy Theses

Department of Respiratory Therapy

7-31-2012

In Vitro Evaluation oF Aerosol Drug Delivery With And Without
High Flow Nasal Cannula Using Pressurized Metered Dose Inhaler
And Jet Nebulizer in Pediatrics
Mahmood A. Alalwan
Georgia State University

Follow this and additional works at: https://scholarworks.gsu.edu/rt_theses

Recommended Citation
Alalwan, Mahmood A., "In Vitro Evaluation oF Aerosol Drug Delivery With And Without High Flow Nasal
Cannula Using Pressurized Metered Dose Inhaler And Jet Nebulizer in Pediatrics." Thesis, Georgia State
University, 2012.
doi: https://doi.org/10.57709/3068196

This Thesis is brought to you for free and open access by the Department of Respiratory Therapy at ScholarWorks
@ Georgia State University. It has been accepted for inclusion in Respiratory Therapy Theses by an authorized
administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.

IN VITRO EVALUATION OF AEROSOL DRUG DELIVERY WITH AND
WITHOUT HIGH FLOW NASAL CANNULA USING PRESSURIZED METERED
DOSE INHALER AND JET NEBULIZER IN PEDIATRICS
By
Mahmood Ahmed Alalwan
A Thesis
Presented in Partial Fulfillment of Requirements for the
Degree of
Masters of Science
in
Health Sciences
in
the Division of Respiratory Therapy
in
Byrdine F. Lewis School of Nursing and Health Professions
Georgia State University
Atlanta, Georgia
2012

NOTICE TO BORROWERS
All theses deposited in Georgia State University library must be used in accordance with
stipulations prescribed by the author in the preceding statement. The author of this thesis
is:
Mahmood Ahmed Alalwan
660 Ralph McGill Blvd NE
Atlanta, GA 30312

The director of this thesis is:
Arzu Ari, PhD, RRT, PT, CPFT
Associate Professor
Division of Respiratory Therapy
Byrdine F. Lewis School of Nursing and Health Professions
Georgia State University
Atlanta, Georgia 30303

VITA
Mahmood Ahmed Alalwan
ADDRESS:

660 Ralph McGill Blvd NE #4315
Atlanta, GA 30312

EDUCATION:
M.S.

2012

Georgia State University

B.S

2007

King Faisal (Dammam) University
Respiratory therapy

PROFESSIONAL EXPERIENCE
2008 - 2009

Staff respiratory therapist in King Faisal Specialist Hospital
and Research Center Riyadh, Saudi Arabia

2007 - 2008

Internship in King Faisal Specialist Hospital and Research
Center
Riyadh, Saudi Arabia

PROFESSIONAL SOCITIES AND ORGANIZATION
April 2012 – Present
Lambda Beta
2009 - Present
American Association for Respiratory Care
PRESENTATION AND PUBLICATION

ACKNOWLEDGMENTS
I would like to thank the Respiratory Therapy Department at Georgia State
University for the use of their facilities and supplies utilized in order to complete this
thesis. Special thanks go to Dr. Arzu Ari for all the time, guidance, and advice she
dedicated to this thesis and me. Her deep knowledge and expertise made this course a
challenging but enjoyable experience. Her passion for research made me realize how
important and fun research could be. Dr. Jim Fink has my sincere gratitude for his
commitment to this thesis and his assistance in conducting the experiments. I also would
like to thank Mr. Bob Harwood for his support and encouragement, as well as for his
thorough revisions and recommendations. Also, I would like to thank Dr. Lawrence
Bryant for his role serving on my committee. My appreciation goes to Mrs. Meryl Sheard
for her magnificent drawings in this study. Finally, I would like to thank my family and
friends for their support through this process, as well as for their patience when I had to
stay away from them for long periods.

ABSTRACT
IN VITRO EVALUATION OF AEROSOL DRUG DELIVERY WITH AND
WITHOUT HIGH FLOW NASAL CANNULA USING PRESSURIZED METERED
DOSE INHALER AND JET NEBULIZER IN PEDIATRICS
By
Mahmood Ahmed Alalwan
Background: HFNC system is a novel device used with aerosol therapy and
seems to be rapidly accepted. Although there are some studies conducted on HFNC and
vibrating mesh nebulizer, the effect of HFNC on aerosol delivery using jet nebulizer or
pressurized metered-dose inhaler (pMDI) has not been reported. In an effort to examine
the effect of HFNC on aerosol deposition, this study was conducted to quantify aerosol
drug delivery with or without a HFNC using either pMDI or jet nebulizer.
Methodology: The SAINT model, attached to an absolute filter (Respirgard II,
Vital Signs Colorado Inc., Englewood, CO, USA) for aerosol collection, was connected
to a pediatric breathing simulator (Harvard Apparatus, Model 613, South Natick, MA,
USA). To keep the filter and the SAINT model in upright position to collect aerosolized
drug, an elbow adapter was connected between the absolute filter and the breathing
simulator. An infant HFNC (Optiflow, Fisher & Paykel Healthcare LTD., Auckland, New
Zealand) ran at 3 l/min O2 was attached to the nares of the SAINT model. Breathing
parameters used in this study were Vt of 100 mL, RR of 30 breaths/min, and I:E ratio of
1: 1.4. Aerosol drug was administered using: 1) Misty-neb jet nebulizer (Allegiance
Healthcare, McGaw Park, Illinois, USA) powered by air at 8 l/min using pediatric aerosol
facemask (B&F Medical, Allied Healthcare Products, Saint Louis, MO, USA) to deliver
albuterol sulfate (2.5 mg/3 mL NS), and 2) Four actuations of Ventolin HFA pMDI (90
µg/puff) (GlaxoSmithKline, Research Triangle Park, NC, USA) combined with VHC
(AeroChamber plus with Flow-Vu, Monaghan Medical, Plattsburgh, NY, USA). Aerosol
was administered to the model with and without the HFNC and another without (n=3).
Drug was collected on an absolute filter, eluted and measured using spectrophotometry.
Independent t tests were performed for data analysis. Statistical significance was
determined with a p value of <0.05.
Results: The mean inhaled mass percent was greatest for pMDI with (p = 0.0001)
or without HFNC (p = 0.003). Removing HFNC from the nares before aerosol treatment
trended to increase drug delivery with the jet nebulizer (p = 0.024), and increased drug
delivery by 6 fold with pMDI (p = 0.003).
Conclusions: Aerosol drug may be administered in pediatrics receiving HFNC
therapy using either jet nebulizer or pMDI. However, using pMDI, either with or without
HFNC, is the best option. When delivering medical aerosol by mask, whether by jet
nebulizer or pMDI, removing HFNC led to an increase in inhaled mass percent.
However, the benefit of increased aerosol delivery must be weighed against the risk of
lung derecruitment when nasal prongs are removed.
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CHAPTER I
INTRODUCTION
Childhood respiratory diseases such as asthma, bronchopulmonary dysplasia
(BPD), and cystic fibrosis (CF) require aerosolized drug therapy as a part of the disease
management. However, infants pose unique challenges for efficacious aerosol delivery
(Ahrens, 2005; Ari & Fink, 2011; Everard, 2004; Rubin et al., 2001). Some of the
challenges that face clinicians during aerosol administration are infant distress, poor
cooperation, and achieving optimum facemask seal.
Distress and poor cooperation during aerosol administration is one of the
recurrent and challenging factors that face clinicians when dealing with pediatrics. For
instance, a study showed that in 69% of the sleep administrations of aerosol to infants
aged between 6 and 23 months, the children woke up and 75% of them were distressed
during the treatment. Moreover, poor cooperation was reported in 29% of the awake
administrations (Esposito-Festen et al., 2006). The level of infant distress is directly
correlated to lung deposition. Amirav et al. (2003) reported an increase in the amount of
extrathoracic deposition with increased infant distress. Furthermore, lung deposition was
reduced significantly to 0.3% in 2 crying infants compared to 2.0% during their quiet
breathing (Tal et al., 1996).
Another factor that plays an important role in determining the lung deposition
during aerosol administration is facemask leak. The facemask, a common alternative to
mouthpiece in infants and small children, functions as an interface between the patient
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and the aerosol delivery device. Not only does lung deposition significantly depend on
the size of the facemask leak, but also the leak position. Different studies reported that
there was a strong correlation between the size of the leak and lung deposition (EspositoFesten et al., 2004; Amirav et al., 2001; Smaldone et al., 2005). Even a leak as small as
0.5 cm could result in greater than 50% reduction of the inhaled mass of the drug
(Esposito-Festen et al., 2004; Amirav et al., 2001; Smaldone et al., 2005). Moreover,
leaks around the nose were associated with less lung deposition than leaks around the
chin (Esposito-Festen et al., 2004). Those factors and challenges clearly emphasize that
aerosol administration in this age group is profoundly different.
In an effort to reduce infant distress, recent aerosol research suggested the use of
high flow nasal cannula (HFNC) as an aerosol delivery device. They proposed that an
aerosol drug could be administered using a vibrating mesh nebulizer with HFNC (Ari et
al., 2011; Bhashyam et al., 2008). Traditionally, HFNC is utilized to avoid mechanical
ventilation, maintain patent airways, and improve gas exchange (Campbell et al., 2006;
Saslow et al., 2006; Shoemaker et al., 2007). There is a rapid increase in the use of the
HFNC in the neonatal and pediatric population. One study revealed a 64% increase in
HFNC usage after its introduction in infants of all gestational ages (Shoemaker et al.,
2007). In addition, 95% of infants born at less than 30 weeks gestation received HFNC at
some point during their hospital stay (Shoemaker et al., 2007).
Significance:
HFNC system is a novel device used with aerosol therapy and seems to be rapidly
accepted. Although there are some studies conducted on HFNC and vibrating mesh
nebulizer, the effect of HFNC on aerosol delivery using jet nebulizer or pressurized
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metered-dose inhaler (pMDI) has not been reported. Also, there is no evidence to support
keeping or removing the HFNC when a facemask is used during aerosol drug delivery.
Thus, more research is required to detect the effects of the presence of HFNC systems on
lung deposition during aerosol administration. In an effort to examine the effect of HFNC
on aerosol deposition, this study is to quantify aerosol drug delivery with or without a
HFNC using either pMDI or jet nebulizer. It would establish a guideline for the clinicians
to make an informed decision in determining the most efficient way to administer aerosol
drug in concurrence with the HFNC therapy.
Hypothesis:
Keeping HFNC in the nares of pediatrics during aerosol therapy with pMDI or jet
nebulizer would decrease drug delivery to the lungs.
Purpose:
The purpose of this study is to quantify aerosol drug delivery in pediatrics with or
without a HFNC using either pMDI or jet nebulizer.
Research Question:
During HFNC therapy in pediatrics, what is the most efficient way to administer
inhaled medications using jet nebulizer or pMDI with or without HFNC?
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CHAPTER II
REVIEW OF THE LITERATURE
Introduction:
This is a literature review of the articles published in the area of aerosol research
and high flow nasal cannula in the pediatric population. Literature was obtained using
PubMed, MEDLINE with Full Text, and CINAHL Plus with Full Text. Different terms
were used for the term aerosol such as nebulizer, aerosols, vaporizers, bronchodilator,
nebulization, inhalation therapy, aerosol therapy, metered dose inhaler, MDI, small
volume nebulizer, SVN, jet nebulizers, and inhalers in pediatrics. For the research on
aerosol delivery via facemask, terms used were facemask, facemask leak, facemask
effects; they were combined with aerosol search terms. For the research on high flow
nasal cannula, search terms used were high flow nasal cannula, HFNC, nasal cannula,
and heated high flow nasal cannula; they were also combined with aerosol search terms.
Articles were divided into four sections: in vivo aerosol research, in vitro aerosol
research, high flow nasal cannula, and aerosol delivery via HFNC. This research
incorporated twenty years of references, ranging from 1991 to 2011. All references were
peer-reviewed and written in English.
In Vivo Aerosol Research:
Chua et al. (1994) conducted a study on 20 asymptomatic children with CF.
Twelve were sleeping infants aged between 0.3 and 1.4 years (median age 0.8 years), and
eight older children aged between 6.3 and 18.0 years (median age 10.8 years). The aim

4

was to quantify aerosol deposition in children of wide age range. They used a nebulizer to
administer radiolabelled normal saline with a flow of 9 l/min. Planar and single-photon
emission computed tomography scans were obtained after aerosol administration. They
found that the total lung deposition in the infants who were asleep (median 1.3%) and for
older children (median 2.7%).
Amirav et al. (2003) conducted a study on 14 wheezy infants (mean age 8
months) to compare aerosol lung deposition using a small volume nebulizer (SVN) with
facemask and prototype hood. Radiolabelled salbutamol was administered to the subjects
randomly by SVN at a flow of 8 l/min with either hood or facemask. Salbutamol delivery
was evaluated using gamma scintigraphy. They found that there was no significant
difference in total lung deposition; mean total lung deposition was 2.4% with the mask
and 2.6% with the hood.
Amirav et al. (2005) conducted a randomized, double-blinded, controlled trial on
49 infants (mean age ± SD, 2.75 mo ± 2.2 mo) diagnosed with viral bronchiolitis to
compare aerosol drug delivery using Aeroneb Go Nebulizer (Aerogen, Inc) with either
hood or facemask. Subjects were divided into 2 groups, hood group and facemask group.
To use both devices on all subjects, half of each group received 1.5 mg epinephrine in 4
mL of 3% saline via one of the devices (hood or facemask) followed immediately by
placebo treatment (normal saline) via the other device, while the other half received the
opposite order. Therapy was repeated 3 times daily until discharge. Outcome measures
included clinical scores and parental preference. They found a significant improvement in
clinical severity scores after the aerosol treatment in both groups on day 1, 2, and 3 after
admission (hood group: 15%, 15.4%, and 16.4%, respectively; facemask group: 17.5%,
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12.1%, and 12.7%, respectively); no significant difference between the two groups was
observed. In addition, 80% of parents preferred the hood over the facemask.
Tal et al. (1996) conducted a study on 15 infants and children (mean age 21
months) with chronic airway obstruction (asthma, BPD, and CF) to assess aerosol
deposition in the lower respiratory tract and gastrointestinal tract. One puff of
radiolabelled salbutamol was administered by pMDl via an Aerochamber spacer
combined with mask. Immediately after administration subjects were scanned with a
gamma camera. They found that mean aerosol deposition was 1.28% ± 0.77% in the
oropharynx, 1.97% ± 1.4% in the lungs, and 1.11% ± 2.4% in the stomach. In addition,
lung deposition was reduced significantly to 0.3% in 2 crying infants compared to 2.0%
during their quiet breathing.
Mallol et al. (1996) conducted a study on 20 asymptomatic children with CF to
quantify aerosol deposition in the respiratory system. They used 2 different jet nebulizers,
Bennett Twin which produces 7.7 µm mass median diameter (MMD) and Hudson UpDraft II which produces MMD of 3.6 µm, to administer radiolabelled normal saline.
Subjects were divided into 3 groups: group A consisted of 10 children that received
aerosol using Bennett Twin jet nebulizer while sedated. Group B consisted of 5 children
that received aerosol via Bennett Twin jet nebulizer while awake. Group C consisted of 5
children that received aerosol using Hudson UpDraft 11 jet nebulizer while awake.
Subjects and equipment were scanned using a gamma camera on completion of
nebulization. They found that total lung deposition in group A was 0.97 ± 0.35%, group
B 0.76 ± 0.36%, and group C 2.0 ± 0.71%. In groups A and B, the deposition occurred
mainly in the trachea and main bronchi. Deposition in the pharynx, mouth, and nose was
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least in group C. No correlation was detected between aerosol deposition in the
respiratory system and with age, weight, height, or sedation. Aerosol deposition was
influenced mainly by aerosol particle size.
Amirav et al. (2002) conducted a study on 12 children (mean age ± SD, 8 mo ± 4
mo) with acute respiratory syncytial virus bronchiolitis to evaluate the distribution
characteristics of aerosolized bronchodilators to the lower respiratory tract. They used the
Micromist jet nebulizer (Hudson Respiratory Care Inc.) attached to a facemask operated
at 8 l/min oxygen to administer radiolabelled albuterol to the subjects. Total body and
lung deposition and pulmonary distribution of the aerosol were measured using
scintigraphy. They found that 1.5% ± 0.7% of the drug dose leaving the nebulizer
deposited in the right lung, with just about 0.6% penetrating to the peripheral lung zone.
7.8% ± 4.9% deposited in the upper respiratory tract and gastrointestinal tract and 10%–
12% remained on the face. No correlation was detected between aerosol deposition and
clinical response (e.g. SO2, HR, RR), height, weight, or body surface area.
Salmon et al. (1990) conducted a study on 9 wheezy children aged between 9
months and 3 years (median 16 months) and 7 healthy adults to evaluate aerosol delivery
to the lungs. They used an Acorn nebulizer (Medic Aid) with Hudson oxygen facemask
(Henleys Medical Supplies) to deliver sodium cromoglycate to the children and adults. In
addition, they delivered the same medication by pMDI, spacer, and mask to the children.
The medication concentration was evaluated in urine samples collected in a timely
manner to estimate lung deposition. In all subjects tested, they found that merely 0.13% 0.61% of the nominal dose was detected in the urine, which represents an estimated 0.3%
- 1.5% deposited in the lung.
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Wildhaber et al. (1999) conducted a study on seventeen children (2-9 years) with
stable asthma to compare aerosol deposition in the lungs from a nebulizer and a pMDI
with nonstatic holding chamber. The subjects were divided into two groups: group A 2-4
years and group B 5-9 years. They administered radiolabelled salbutamol with the
nebulizer and pMDI randomly to the subjects. Lung deposition was evaluated with a
gamma camera. With the nebulizer, they found that the mean total aerosol deposition was
5.4% and 11.1% for group A and group B, respectively. With the pMDI and holding
chamber, they found that the mean total aerosol deposition was 5.4% and 9.6% in group
A and group B, respectively.
Fok et al. (1996) conducted a study on 23 preemies, 10 intubated and 13
spontaneously breathing infants, with or at high risk of developing BPD to evaluate
aerosol deposition in the lungs. They administered radiolabelled salbutamol to every
infant twice on separate occasions. Spontaneously breathing infants received aerosol
using a tightly sealed facemask (Laerdal Resuscitation Mask; Laerdal) with either a jet
nebulizer or pMDI and Aerochamber spacer (Aerochamber, Trudell Medical). Intubated
infants received aerosol using either a jet nebulizer or a pMDI and Aerochamber (MV15
Aerochamber, Trudell) connected to the ventilator circuit. After administration, imaging
was obtained using a gamma camera. Only data from 18 infants (11 spontaneous and 7
intubated) were available for the analysis of regional deposition. They found that the
mass median aerodynamic diameters (MMAD) was 1.88 µm and geometric standard
deviation (GSD) was 1.45 µm of the pMDI aerosols after passing the endotracheal tube
(ETT) for the intubated infants; the spontaneously breathing infants had MMAD of 1.83
µm and GSD of 1.50 µm after exiting the mask. The MMAD and GSD of the aerosols of
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the jet nebulizer were 0.83 µm and 1.69 µm, respectively, for the intubated infants, and
1.01 µm and 1.64 µm for the spontaneously breathing infants. In addition, they found that
aerosol deposition in the lungs of spontaneously breathing infants was between 0.12 %
and 2.26% using the pMDI and between 0.12% and 0.66% of the initial nebulizer
reservoir. For the intubated infants, aerosol deposition in the lungs was between 0.35%
and 2.12% using the pMDI, and 0.22% of the initial nebulizer charge.
Esposito-Festen et al. (2006) conducted a study on thirty infants aged between 6
and 23 months with recurrent wheeze to examine the possibility of aerosol administration
via a pMDI and spacer (NebuChamber, 250 mL, AstraZeneca) in sleeping infants in daily
life setting. Over a period of 21 days, parents were instructed to administer 2 extra puffs
of budesonide (Pulmicort, 200 ug; AstraZeneca) to the children’s regular treatment; 1
puff while awake and another while asleep. Parents also added a new filter between the
chamber and the facemask before each administration to measure aerosol deposition.
Scoring of the children’s asthma symptoms, degree of cooperation, and feasibility of
administration on diary cards was done by the parents. They found that administration of
aerosol to most of the infants while asleep was not superior to administration while
awake. The mean filter dose ± SD % of the nominal dose for the sleep administration was
16 ± 13%, and that for the awake administration was 47 ± 26% (p = 0.007). During sleep
administration, 69% of the children woke up during the treatment with distress. Poor
cooperation was reported in twenty nine per cent of the administrations while awake.
Erzinger et al. (2007) conducted a study on 8 asymptomatic children aged
between 18 months and 3 years with recurrent wheeze. They hypothesized that a minor
air leak in the facemask can significantly reduce lung deposition. They administered
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radiolabelled salbutamol with either vent-assisted nebulizer (PariBaby with Pari
facemask no. 2) or a pMDI attached to a holding chamber (Aerochamber with an
Aerochamber 2nd generation face mask; Trudell Medical). Aerosol deposition was
measured using a gamma camera and expressed as a percentage of the nominal dose.
They found that lung deposition in 2 subjects with a facemask leak was 0.2% (pMDI) and
0.3% (nebulizer). In 2 subjects who were screaming and without facemask leak, lung
deposition was 0.6% (pMDI) and 1.4% (nebulizer). In 4 subjects who were quietly
breathing and without facemask leak, lung deposition was between 4.8% and 8.2%. In
addition, mask deposition ranged between 0.8% and 5.2%, and face deposition ranged
between 2.6% and 8.4%.
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In Vitro Aerosol Research:
Sangwan et al. (2004) conducted an in vitro study to quantify facial and eye
aerosol delivery in a model simulating an average 2-year-old child’s face facsimile
(Massachusetts Institute of Technology, Cambridge, MA). They used a jet nebulizer to
administer radiolabelled normal saline; which was inhaled using a piston pump (Harvard
Pump, South Natick, MA) attached to facsimile. A pediatric tidal volume (Vt) of 50 mL,
respiratory rate (RR) of 25 breaths/minute, and duty cycle (inspiratory time/total
respiratory cycle time) of 0.4 were used. To quantify aerosol deposition at the mouth, a
filter was placed between the piston pump and the mouth opening. Seven commercially
available facemasks (Laerdal, Laerdal Medical Corp.; Sealflex, Caradyne Ltd; Ferraris
Panda, Ferraris Medical Ltd; PariBaby&Pari Bubble, Pari Respiratory Equipment, Inc;
Salter, Salter Labs; Hudson, Hudson Respiratory Care, Inc.) in combination with three jet
nebulizers (Pari LC Plus, PARI Respiratory Equipment, Inc.; MistyNeb, Allegiance;
AeroTech II, CIS-US, Inc), which produce different sizes of particles, were tested for
aerosol deposition in the lungs, on the face and in the eyes. They found that 2.24–5.96%
of the nominal dose was inhaled; 0.44–2.34% deposited on the face; 0.09–1.78%
deposited in the eyes. There was a leak with all facemasks with substantial facial and eye
deposition. Additionally, aerosol deposition in the eyes and face was affected by the
facemask design and aerosol particle size.
Laube et al. (2010) conducted an in vitro study using four copies of a 9-month-old
infant model, the Sophia Anatomical Infant Nose-Throat (SAINT), to measure the
aerosol deposition of albuterol within the nose and lungs. The model was connected to a
computer-operated breathing simulator (PARI Breath Simulator, PARI GmbH). They
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administered radiolabelled albuterol to the four copies of the SAINT model continuously
over thirty seconds by an IPI nebulizer (IPI Medical Products, Inc.). The nebulizer was
run by an air compressor (Thomas Model 1020) at 10.5 l/min. a 15-cm corrugated tube
with a plastic funnel-shaped facemask was used to deliver aerosol; the mask was not held
tightly against the face. The simulator’s RR, inspiratory time, expiratory time, and duty
cycle were 30 breaths/min, 0.9 sec, 1.1 sec, and 0.45, respectively. Three different Vt’s
(50, 100, and 200 mL) were used. Aerosol deposition was measured using a gamma
camera as percentage of discharged dose. They found that the mean MMD for the
nebulizers used was 4.78± 0.18 µm. Lung deposition was alike for the different Vt’s; it
was 7.17± 0.01% at 50 mL, 9.34±0.01% at 100 mL, and 9.41±0.02% at 200 mL. On the
contrary, nose deposition increased when Vt was increased; it was 4.40±0.02% at 50 mL,
11.39±0.02% at 100 mL, and 22.12± 0.02% at 200 mL. Aerosol lost in the environment
was significantly higher at 50 mL Vt (71.99± 0.02%), compared to 200 mL
(53.81±0.04%).
Esposito-Festen et al. (2004) conducted an in vitro study using a SAINT model
(SAINT model, Erasmus MC) that was connected to a computer-controlled breathing
simulator; the study was to investigate the relationship between size and position of a
mask leak on spacer output and lung dose. The simulator’s set parameters were duty
cycle of 0.42, Vt of 100 mL, and RR 30 breaths/min. They administered budesonide
pMDI (Pulmicort 200 mg, AstraZeneca) to the model via a metal spacer (NebuChamber,
AstraZeneca) with a round-shaped resuscitation facemask (Galemed). Nine facemask
leaks (0-1.5 cm2) close to the nose (nose position) or the chin (chin position) were tested.
The spacer output was trapped by a filter placed between spacer and facemask; the lung
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dose was trapped by a filter placed between model and breathing simulator.
Quantification was done by a validated high-performance liquid chromatography
(HPLC), and expressed as percentage of the nominal dose. They found that the nose
position leaks and their corresponding spacer output (mean output%) were 0 (50%), 0.05
(38%), 0.1 (28%), 0.16 (12%), 0.2 (10%), 0.3 (6%), and greater than 0.4 (0%). The chin
position leaks and their corresponding spacer output (mean output%) were 0 (50%), 0.05
(40%), 0.1 (31%), 0.16 (11%), 0.2 (9%), 0.3 (4%), and greater than 0.4 (0%). The nose
position leaks and their corresponding lung doses (mean dose%) were 0 (10%), 0.05
(8%), 0.1 (6%), 0.16 (3%), 0.2 (3%), 0.3 (1%), 0.4 (0%), 0.5 (0%), 1.0 (0%), and 1.5
(0%). The chin position leaks and their corresponding lung doses (mean dose%) were 0
(10%), 0.05 (9%), 0.1 (8%), 0.16 (6%), 0.2 (6%), 0.3 (5%), 0.4 (1%), 0.5 (1%), 1.0 (0%),
and 1.5 (0%).
Smaldone et al. (2007) conducted an in vitro study to determine the effect of
facemask seal, mask vents and nebulizer flow on aerosol drug deposition in the lungs in
children using nebulizers and facemasks. They used a pediatric face facsimile and piston
pump to simulate breathing with Vt 50 mL, RR 25 breaths/min, and duty cycle 0.4 for all
of the tests. They administered radiolabeled saline using Pari LC jet plus nebulizer run at
4 or 8 l/min with front-loaded and bottom-loaded masks. A gamma camera was used to
assess deposition in the face and eyes. A filter was placed between the face and piston
pump to measure drug delivery to the lungs and expressed as a percentage of the nominal
dose. Nebulizer flows of 4 and 8 l/min were tested. In their preliminary experiments, they
tested different facemasks including original Laerdal Facemask (A), a bottom-vented
Laerdal Facemask (B), and eye-cutouts Laerdal Facemask (C) to study the effects of
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vents and nebulizer flow. These observations led to the design of a mask prototype; a
front-loaded modified Pari Bubbles facemask with a vent and eye cutouts (D). This
prototype was compared to a bottom-loaded Salter I-Guard facemask (E) combined with
NebuTech HDN nebulizer. They found that the inhaled mass (Mean ± SE%) with its
corresponding mask were 6.38 ± 0.42% (A), 6.55 ± 1.42% (B), 7.69 ± 1.68% (C), 8.78 ±
0.98% (D), and 2.33 ± 0.22% (E). At the flow of 8 l/min, the inhaled mass was reduced
by nearly a half. Facial depositions were 1.76 ± 0.17% (A), 0.72 ± 0.07% (C), 0.66 ±
0.07% (D), and 1.43 ± 0.16% (E). Eye depositions were 1.14 ± 0.15% (A), 0.15 ± 0.02%
(C), 0.09 ± 0.01% (D), and 0.31 ± 0.03% (E). At 8 l/min nebulizer flow, facial and eye
deposition remained approximately the same.
Janssens et al. (2004) conducted an in vitro study using the SAINT model
connected to a simulator to evaluate the effect of Vt, RR, and pMDI/spacer combination
on aerosol deposition of 4 pMDI/spacer combinations, which are used for infants.
Spontaneous breathing patterns were simulated with duty cycle 0.42, Vt’s of 25, 50, 75,
100, 150, 200 mL were tested with RR of 30 breaths/min; and RR’s of 20, 30, 42, 60, 78
breaths/min were tested with Vt of 100 mL. pMDI’s used were Budesonide (Pulmicort
200 mg, AstraZeneca) and Fluticasone HFA (Flixotide 125 mg, GlaxoWellcome).
Spacers used were Babyhaler (polycarbonate), Nebuchamber (metal), and Aerochamber
(plastic). pMDI’s were combined with the spacers as the following:
budesonide/Nebuchamber, fluticasone/Babyhaler, budesonide/Aerochamber, and
fluticasone/Aerochamber. To reduce electrostatic charge, plastic spacers were detergent
coated. A filter positioned between spacer and facemask to measure spacer-output dose
or between model and breathing simulator to measure aerosol deposition in the lungs. An
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impactor was used to determine aerosol particle size. They found a significant positive
correlation between spacer output and Vt but not RR. There was an initial increase in
lung deposition with increased Vt from 25 to 50 mL (Nebuchamber, Aerochamber) or to
100 mL (Babyhaler). However, lung deposition was decreased, with further increase in
Vt and RR. Maximum lung doses, expressed as percentage of nominal dose, at Vt of 50
mL were 11%, 9%, and 16% for budesonide/Nebuchamber, budesonide/Aerochamber,
and fluticasone/Aerochamber, respectively. Maximum lung dose at Vt of 100 mL was
19% for fluticasone/Babyhaler. Irrespective of spacer type, aerosol deposition in the
lungs generated by fluticasone was 1.5–6-fold higher compared with budesonide. MMAD
decreased with increasing Vt and RR. Aerosol particles <2.1 mm was independent of Vt
and RR for deposition in the lungs. Lung dose decreased with increasing inspiratory flow
(increasing Vt or RR) by increasing impaction of coarse particles in the upper airways.
Deposition of particles <2.1 mm is relatively flow independent. If electrostatic charge of
spacers is minimized, lung dose is pMDI dependent and relatively spacer independent.
Smaldone et al. (2005) conducted an in vitro study to measure the effect of the
facemask on aerosol drug delivery using a pediatric breathing simulator connected to a
face. For aerosol administration, they used Budesonide (0.25 mg) with 2 nebulizer
brands: Hudson Up-draft II with standard pediatric facemask, and breath enhanced Pari
LC Plus with Bubbles the fish facemask; a fluticasone propionate (220 µg) pMDI with 2
valved-holding chambers (VHCs) brands were used: AeroChamber Plus with medium
ComfortSeal facemask, and OptiChamber with medium facemask. VHCs were tested in
non-detergent-coated and detergent-coated conditions. A filter was positioned between
the simulator and the face. The simulator’s Vt, RR, and duty cycle for breathing pattern
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(1) were 207 mL, 37 breaths/min, 0.41 and breathing pattern (2) 75 mL, 25 breaths/min,
0.40. The delivery systems described above were tested in three conditions; the first
condition with a constant flow to deliver all generated aerosol to the filter; the second
condition with applied breathing pattern with tight seal; the third condition with applied
breathing pattern with possible facemask leak. They found that in the first condition the
drug output was 45.8 ± 4.4% and 46.0 ± 7.2% for Hudson and Pari nebulizers,
respectively; 35.5 ± 1.0% and 18.2 ± 3.3% for non-detergent coated AeroChamber and
OptiChamber, respectively; 50.8 ± 4.7% and 38.8 ± 4.4% for detergent coated
AeroChamber and OptiChamber, respectively. In the second condition, they found that
the inhaled mass ranged between 9.6 ± 0.7 and 24.3 ± 3.1% for the nebulizers, 0.7 ± 0.5%
and 7.7 ± 1.6% for the non-detergent coated VHCs, and 27.2 ± 1.4% and 53.3 ± 6.2% for
the detergent coated VHCs. In the third condition, they found that the inhaled mass
ranged between 4.1 ± 0.8% and 19.3 ± 2.3% for the nebulizers, 1.0 ± 0.2% and 3.1 ±
2.4% for the non-detergent coated VHCs, and 4.0 ± 1.6% and 28.6 ± 2.5% for the
detergent coated VHCs.
Amirav et al. (2001) conducted a preliminary in vitro study followed by an in
vivo study to evaluate whether parents can keep a good facemask seal in children. They
studied NebuChamber mask (Astra Draco AB), BabyHaler mask (infant size 2; Glaxo),
and AeroChamber mask (child mask; Trudell Medical), combined with frequently used
pediatric VHCs and compared them with the seal obtained with the Hans Rudolph mask
(#2; Hans Rudolph, Inc.). The preliminary in vitro study was conducted using albuterol
pMDI, the NebuChamber VHC, electrostatic filter inserted between the NebuChamber
and the mask, a screen pneumotachograph from a portable spirometer (Flowscreen; E.
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Jaeger) inserted between the mask and the filter holder, and a cooperative healthy adult to
simulate breathing. In vivo studies were conducted on 30 asymptomatic children (mean
age 3.2 ± 1.4 years) with asthma to evaluate facemask leak for the 4 masks by measuring
ventilation with a pneumotachograph connected to the outlet of the mask. The facemask
was held in place by experienced parents who were not given any instructions. Maximal
voluntary ventilation (MVV) was measured. Ten patients repeated the tests, however,
unlike the first time, the parents were instructed continuously and encouraged to maintain
a tight facemask seal against the child’s face. The in vitro studies showed that there was a
positive linear relationship between the measured ventilation and the dose deposited in
the filter. They found that MVV’s (mean ± SD) were 4.22 ± 0.93, 2.89 ± 0.81, 4.24 ±
0.85, and 3.82 ± 1.19 l/min for the Hans Rudolph, NebuChamber, AeroChamber,
BabyHaler masks, respectively. Intraindividual variability ranged between 24% and 45%
but the greatest variability was found with the NebuChamber mask. MVV’s during
coached sessions were significantly higher than the uncoached sessions.
High Flow Nasal Cannula (HFNC):
Saslow et al. (2006) conducted a study on 18 preterm infants weighing less than 2
kg at birth to compare their work of breathing (WOB) with HFNC and nasal continuous
positive airway pressure (NCPAP). Infants were studied on both devices and received
NCPAP at 6 cm H2O with nasal prongs through a ventilator and HFNC via Vapotherm at
3, 4, and 5 l/min randomly. Infants served as their own control. Vt was obtained using
respiratory inductance plethysmography coupled with facemask pneumotachography for
calibration. Changes in end distending pressure were calculated using an esophageal
balloon to estimate pleural pressure. Elastic, resistive, and inspiratory WOB and
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respiratory parameters were calculated. They found that there were no differences in the
WOB for all settings. Compliance was increasing with increased HFNC flow but it was
only statistically significant at flow of 5 l/min. Changes in end distending pressure was
statistically significantly only with HFNC at 5 l/min.
Spence et al. (2007) conducted an observational study over one year on a
convenience sample of 14 stable infants who required either HFNC or NCPAP. The aim
of the study was to measure the intrapharyngeal pressure (IPP) generated by HFNC at
different flow rates using IPP manometry. They found that flow rates of 1, 2, 3, 4 and 5
l.min-1 (l/min) generated an IPP of 1.70 ± 0.34, 1.75 ± 0.2, 2.62 ± 0.28, 3.78 ± 0.44, and
4.84 ± 0.51 cm H2O respectively. No correlation was found between the size of the baby
and the IPP generated.
Shoemaker et al. (2007) conducted a retrospective database review composed of
two parts. The first part of the study was to assess the frequency of usage, safety and
clinical utility of HFNC in two tertiary neonatal intensive care units. The second part
compares outcomes of premature infants, born at less than 30 weeks gestation, who
received either NCPAP or HFNC as an early respiratory support mode. The first part of
the study revealed a 64% increase in HFNC usage after its introduction in infants of all
gestational ages while the usage of NCPAP dropped from 19% to 4%. Ninety five per
cent of infants born at less than 30 weeks gestation received HFNC at some point during
their hospital stay whereas only 12% received NCPAP. There were no differences in
death or BPD, but ventilator-days per patient were decreased from19.4 to 9.9 days
following introduction of HFNC. The second part of the study revealed no differences in
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deaths, ventilator-days, BPD, blood infections or other outcomes. 40% of infants were
intubated for failing early NCPAP compared to 18% with early HFNC.
Campbell et al. (2006) conducted a study on 40 intubated preterm infants
weighing less than or equal to 1250 g at birth to compare the feasibility of continuous
positive airway pressure (CPAP) support generated by HFNC with conventional CPAP
for prevention of reintubation. The infants were randomized to HFNC or 5 to 6 cm H2O
NCPAP (VIASYS) at extubation. HFNC system consisted of a gas source, air-oxygen
blender and a nonheated bubble humidifier delivering air/oxygen via standard nasal
cannula; a formula was used to calculate the flow required to generate a CPAP level of
4.5 cm H2O. Primary outcome was the incidence of reintubation within 7 days.
Secondary outcomes included change in O2 use and frequency of apnea and bradycardia
postextubation. They found 12 of 20 infants randomized to HFNC were reintubated
compared to 3 of 20 using NCPAP. The HFNC group had increased oxygen use and more
apneas and bradycardias postextubation.
Aerosol Delivery Via HFNC:
Bhashyam et al. (2008) conducted an in vitro study to evaluate the possibility of
delivering aerosols through adult, pediatric, and infant nasal cannulas. They used an
aerosol delivery system composed of an Aeroneb Solo nebulizer (Aerogen, Inc.) which
was positioned downstream of a Fisher Paykel humidifier (Fisher & Paykel Healthcare
Inc.), followed by nasal cannula driven by 3 l/min O2. A corrugated tube was placed over,
and sealed around, the prongs of the cannula as a collection system. A single cartridge
HEPA filter (HEPA-Lites, Teleflex Medical) was placed at the end of the collection
system. They tested this delivery system with and without inhalation-only flows using a
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Harvard Lung. Vt, RR, and I:E ratio were 150 mL, 25 breaths/min, 1:1; 300 mL, 18
breaths/min, 1:1; and 550 mL, 15 breaths/min, 1:1 for the infant cannula, pediatric
cannula, and adult cannula, respectively. They administered 4 mL radiolabelled deionized
water by the nebulizer. Total cannula output in the HEPA filter and losses were measured
as a percentage of the nominal dose using a nuclear medicine dose calibrator
(Radioisotope Calibrator CRC-4, Capintec, Inc.). Aerosol particle size was measured
using laser-diffraction techniques (Malvern Instruments) at three different points. They
found that total cannula output was 8.4-25.1% and 18.6–26.9% without and with the
Harvard Lung, respectively. The pediatric cannula output was 18.1 ± 4.2 and 25.4 ± 1.7
without and with the Harvard Lung, respectively. Volume median diameters were 2.2 ±
0.2 µm and 1.9 ± 0.3 µm from the adult and pediatric cannulas, respectively. 90% of the
aerosol volume was in sizes smaller than 4.2 ± 0.4 µm and 3.8 ± 0.5 µm for the adult and
pediatric cannulas, respectively. On the one hand, system losses were highest in the
nebulizer–humidifier connectors, heated tube, and humidifier. On the other hand, losses
in the nebulizer were the lowest.
Ari et al. (2011) conducted an in vitro study to measure aerosol deposition using
two different gases; one is 100% oxygen (O2) and the other is heliox (80/20%) in a
pediatric-breath simulator. The pediatric-breath simulator was composed of a ventilator
(Galileo, Hamilton, Inc., Reno, NV), a dual chamber test lung (Michigan Instruments,
Grand Rapids, MI), and an absolute filter. A simulated inhalation and exhalation was
created in one of the chambers when the positive pressure applied by the ventilator
displaced the other chamber. From one side, the absolute filter was attached to the
chamber that simulated breathing. The other side was connected to a t-piece with two
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openings to simulate the nares. Breathing parameters were Vt 100 mL, RR 20
breaths/min, and Itime of 1 sec. They used a vibrating mesh nebulizer (Aeroneb Solo,
Aerogen) to administer albuterol sulfate (2.5 mg/3 mL) via a pediatric HFNC. The
nebulizer was positioned on the inspiratory inlet of a heated humidifier and heated wire
circuit attached to a pediatric nasal cannula (Optiflow, Fisher & Paykel). They tested this
system at two different flow rates, 3 and 6 l/min, for each gas for a total of 12 runs. Drug
was collected, eluted and measured through spectrophotometry (Beckman Instruments,
Fullerton, CA) and expressed as a percentage of the nominal dose. They found that the
mean drug deposition at 3 l/min was 11.41 ± 1.54 and 10.65 ± 0.51 with heliox and O2,
respectively. At 6 l/min, drug deposition was 5.42 ± 0.54 and 1.95 ± 0.50 with heliox and
O2, respectively.
Summary:
Aerosol delivery to infants and small children is significantly different. For
instance, facemask leak, even a small one, could cause a substantial reduction in aerosol
delivery. Aerosol delivery using a combination of pMDI and spacer is at least as effective
as a jet nebulizer. Traditionally, HFNC is utilized to avoid mechanical ventilation,
maintain patent airways, and improve gas exchange. There is a rapid increase in the use
of the HFNC in the neonatal and pediatric population. Recent bench studies suggested
that the nasal route is a viable option for aerosol administration. It was reported that
aerosol administration via vibrating mesh and HFNC may provide a relatively high
inhaled mass.
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CHAPTER III
METHODOLOGY
In Vitro Lung Model:
The SAINT model used in this study is an anatomically correct model of the
upper airways of a young child. It was reproduced from CT scans of the upper airways of
a 9-month-old infant. The nasal airway was open for air passage with the oral passage
closed (Janssens et al., (2001).
The SAINT model, attached to an absolute filter (Respirgard II, Vital Signs
Colorado Inc., Enlgewood, CO, USA) for aerosol collection, was connected to a pediatric
breathing simulator (Harvard Appartus, Model 613, South Natick, MA, USA). To keep
the filter and the SAINT model in upright position to collect aerosolized drug, an elbow
adapter was connected between the absolute filter and the breathing simulator. An infant
HFNC (Optiflow, Fisher & Paykel Healthcare LTD., Auckland, New Zealand) was
attached to the nares of the SAINT model.
The HFNC setup was composed of wick humidifier (MR850JHU, Fisher &
Paykel Healthcare LTD., Auckland, New Zealand), heated-wire circuit, and infant
HFNC. It was operated at a flow of 3 l/min O2. Figure 1 illustrates the experimental setup
of the study.
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Figure 1. The experimental setup of the study
Breathing Parameters:
Breathing parameters used in this study were Vt of 100 mL, RR of 30
breaths/min, and I:E ratio of 1: 1.4. The breathing parameters were verified using NICO 2
monitor (Respironics California Inc., Carlsbad, CA, USA). The 9-month-old baby that
the SAINT model was based on was 10 kg (Janssens et al., 2001). The parameters used
are within the reference values appropriate for a 9-month-old 10-kg baby (Amsallem et
al., 2008; Stick, 1996)
Aerosol Generator Types, Doses, and Operation:
Two types of aerosol devices were used in this study: (1) Jet Nebulizer (2) pMDI.
Jet nebulizer: Misty-neb jet nebulizer (Allegiance Healthcare, McGaw Park,
Illinois, USA) is a traditional pneumatic Bernoulli type nebulizer combined with pediatric
aerosol mask (B&F Medical, Allied Healthcare Products, Saint Louis, MO, USA) was
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used to deliver aerosol. In this study, the jet nebulizer was operated with air; the
flowmeter was set at 8 l/min and albuterol sulfate (2.5 mg/3 mL NS, Nephron
Pharmaceuticals Corporation, Orlando, FL, USA) was placed in the nebulizer medication
reservoir. All of the nebulizers were run continuously until sputter, which took about 5
minutes.
pMDI: Albuterol sulfate pMDI (Ventolin HFA, GlaxoSmithKline, Research
Triangle Park, NC, USA) combined with VHC (AeroChamber plus with Flow-Vu,
Monaghan Medical, Plattsburgh, NY, USA) were used for aerosol administration. Four
puffs of Ventolin HFA (90 µg/puff) were administered into VHC. Each pMDI canister
was well shaken, warmed to hand temperature, and primed using the standard actuator
provided by the manufacturer before each experimental run. During testing, 4 puffs were
actuated at the beginning of inspiration at periods of 20 seconds. To reduce interoperator
variability, the same operator actuated all pMDI doses. The VHC was held horizontally,
with the pMDI in a vertical position during actuation.
Study Design:
A total of 12 runs were conducted with albuterol sulfate administered using the jet
nebulizer and pMDI in two different conditions; one with the HFNC and another without
the HFNC. Figure 2 illustrates the organizational design of the study.
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Figure 2 Organizational design of the study
In Vitro Measurements:
The absolute filter placed between the breathing simulator and the SAINT model
was used to collect aerosolized albuterol with each run. Elution of the drug from the filter
was performed with 0.1 M normal hydrochloric acid for 3 min with gentle agitation, and
analyzed via spectrophotometry (Beckman Instruments, Fullerton, CA), at a wavelength
of 276 nm. Calibration of the spectrophotometer was performed using only the solvent
before the trials to determine wavelength accuracy and it was set to zero before every
analysis. Albuterol eluted from the filter was quantified and expressed as a per cent of
drug delivered from the nominal dose.
Data Analysis:
The amount of drug deposited in the filter was expressed as a percentage of the
drug delivered from the nominal dose (jet nebulizer) and emitted dose (pMDI) during
each trial experiment. Descriptive statistics were calculated for the means and standard
deviations of each aerosol generator type with the presence or absence of HFNC.
Independent samples t tests were performed to determine significant differences between
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the percent inhaled dose measured with or without the HFNC, using the jet nebulizer and
the pMDI. Statistical significance was determined with a p value of <0.05.
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CHAPTER IV
RESULTS
Deposition of albuterol on the filter (inhaled mass) was expressed as percent of
the nominal dose inhaled by the model. In addition to the p values, Table 1 shows the
mean and standard deviation of inhaled mass obtained with each aerosol device with or
without HFNC.
Table 1. Mean percent deposition of albuterol on the filter (Inhaled mass) using jet
nebulizer and pMDI with the pediatric simulated breathing pattern
Aerosol Device

With HFNC

Without HFNC

p-value

Jet Nebulizer

2.91 ± 0.23

6.05 ± 1.53

0.024

pMDI

6.04 ± 0.28

39.54 ± 8.98

0.003

p-value

0.0001

0.003

The mean inhaled mass percent was greatest for pMDI with (p = 0.0001) or
without HFNC (p = 0.003). Removing HFNC from the nares before aerosol treatment
trended to increase drug delivery with the jet nebulizer (p = 0.024), and increased drug
delivery by 6 fold with pMDI (p = 0.003). Figure 3 shows the mean inhaled mass (µg)
using both devices with or without HFNC. While the jet nebulizer delivered more drug
than the pMDI with HFNC (p<0.05), there was no difference without HFNC.
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Figure 3. Mean inhaled mass using the jet nebulizer and pMDI with or without HFNC. !
indicates significant difference (p value < 0.05).
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CHAPTER V
DISCUSSION
There are some recent studies conducted on aerosol delivery via HFNC and
vibrating mesh nebulizer. However, the effect of HFNC on aerosol delivery using the jet
nebulizer or pMDI has not been reported. To examine the effect of HFNC on aerosol
deposition, this study quantified aerosol drug delivery with or without HFNC using either
pMDI or jet nebulizer.
The administration of aerosol via facemask with a HFNC in place reduced the
mean percentage of inhaled dose with either jet nebulizer or pMDI, compared to
administration by mask alone. Using the jet nebulizer, inhaled dose was nearly doubled
when HFNC was removed. With pMDI, removing HFNC increased inhaled dose by 6
folds.
The findings of this study using pMDI without HFNC were different from
Janssens et al. (2004). Using similar breathing parameters, Janssens et al. reported a
maximum percent of inhaled dose of 19% while this study found 39.54 ± 8.98% inhaled
mass percent. A similar model was used in both studies, which was composed of a
SAINT model in upright position connected to an absolute filter distal to the trachea
attached to a breathing simulator. Two key differences between the two studies were the
drug/device formulation tested and the valved holding chamber used. They used a
combination of fluticasone HFA pMDI with Babyhaler, while we used Ventolin HFA
pMDI combined with Aerochamber plus with Flow-Vu.
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The inhaled mass as percent of nominal dose (6.05 ± 1.53) using jet nebulizer
without HFNC in this study was similar to that reported by Laube et al. (2010) as the
percent of emitted dose inhaled (9.34 ± 0.01%). Similar breathing parameters and model
were used in both studies. However, different jet nebulizer (IPI nebulizer) powered by air
at 10.5 l/min to administer albuterol sulfate for 30 seconds was used in their study, as
opposed to Misty-neb jet nebulizer powered by air at 8 l/min till sputter was used in this
study. While aerosol was administered through a 15-cm corrugated tube connected to a
funnel-shaped plastic facemask in their study, the jet nebulizer was directly connected to
a commercial pediatric facemask in this study. The reported deposition as the percent of
emitted dose that reached the filter does not account for the residual drug remaining in
the nebulizer, which may overestimate efficiency by 2 – 6 folds compared to percent of
inhaled nominal dose.
Fok et al. (1996), reported differences in lung deposition between pMDI and jet
nebulizer in an infant population between 1 - 4 kg. They administered radiotagged
aerosol drug to spontaneously breathing infants with jet nebulizer and
pMDI/Aerochamber with mask. Using the nebulizer with facemask the lung deposition
was 1.74 ± 0.21% of the nebulized dose and 0.28 ± 0.04% of the initial dose placed in the
reservoir. Actual lung deposition with the pMDI was 0.67 ± 0.17% of the emitted dose.
While deposition was lower with both aerosol generators, so was the range of tidal
volumes (6- 24 mL) in this infant population.
In our study, HFNC appears to reduce aerosol delivery due to the physical
obstruction created by the HFNC, as opposed to unobstructed nasal openings without
HFNC. In addition, the flow of O2 delivered through HFNC represents a significant
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proportion of the model’s minute ventilation, so that flushing gas into the nares acts to
reduce the entry of aerosol into the nasopharynx.
An obvious answer to increasing the aerosol deposition would be to remove the
HFNC during administration of drug. However, there are some clinical consequences of
interrupting the HFNC therapy for aerosol administration. Some of these consequences
may include lung derecruitment and delivery of lower percentage of inspired O2.
The findings of this study, using the jet nebulizer or pMDI applied via mask with
HFNC, were different from studies reporting administration of aerosol via HFNC.
Bhashyam et al. (2008) reported an inhaled dose of 18.6 ± 4% using 3 LPM flow with
infant cannula. The breathing parameters for the infant population used in their study
were Vt of 150 mL, RR of 25 and I:E ratio of 1:1; the higher Vt may overestimate the
inhaled dose. They used a vibrating mesh nebulizer to administer aerosol drug through
infant HFNC system with inhalation-only Harvard lung. Vibrating mesh nebulizers are
reported to have a higher efficiency than jet nebulizers in terms of particles size, low
residual drug volumes and aerosol output. In their study, they used a collection system
composed of a corrugated tube to measure inhaled dose from the cannula as opposed to
an upper airway model. Aerosol losses are expected in the SAINT model between the
nares and trachea.
The results of this study, using jet nebulizer or pMDI with HFNC, were also
different from Ari et al. (2011) reporting a percent of inhaled dose of 10.65 ±0.51 with
flow rates of 3 l/min. They administered albuterol using a vibrating mesh nebulizer
through a pediatric HFNC system run at 3 and 6 l/min O2 while in this study aerosol was
administered using facemask with HFNC. Inhaled dose efficiency of aerosol was reduced
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to < 2% as flow through the HFNC increased to 6 l/min when delivering aerosol through
the HFNC. They expressed the theory that as flow of oxygen increased, the aerosol was
diluted, so the “model” inhaled lower percentage of dose. Vibrating mesh nebulizer has
been reported to be more efficient than jet nebulizer, which could result in a higher
deposition. They used a simulated nares/pharynx in their study, as opposed to an upper
airway model used in this study. Aerosol losses are expected in the SAINT model
between the nares and trachea, resulting in a lower dose. In addition, the I:E of 1:2 used
by Ari et al. as opposed to I:E of 1:1.4 in this study would report a lower inhaled dose of
drug deposited.
Aerosol delivery via HFNC appears to be more efficient option than using
facemask for administration with HFNC in place. Aerosol delivery via HFNC avoids the
obstruction faced when aerosol is delivered using facemask with HFNC. It also maintains
the lung recruitment and percentage of inspired O2, which may reduce infant distress.
Clinical Implications
During HFNC therapy in pediatrics, jet nebulizer is a less efficient device for
aerosol delivery than pMDI. If the patient is stable enough to take the HFNC off for a
short period, the best condition is to administer aerosol using pMDI without HFNC. Even
during HFNC therapy, pMDI is superior to jet nebulizer. Aerosol administration using
pMDI is faster and more effective than jet nebulizer during HFNC therapy. However,
clinical consequences of interrupting HFNC therapy may include lung derecruitment and
delivery of lower percentage of inspired O2.
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Limitations
Only one breathing pattern was examined in this study. Different breathing
patterns would generate more understanding of the variables that affect aerosol drug
delivery with HFNC. In addition, vibrating mesh nebulizer was not tested in this study.
Vibrating mesh nebulizers are reported to have a higher efficiency. This is an in-vitro
study; therefore, an in-vivo study is required to assess the clinical response in pediatrics
receiving aerosol therapy with HFNC therapy.
Future Research Questions
How would different breathing patterns affect aerosol deposition in pediatrics
receiving HFNC therapy? How efficient is the vibrating mesh nebulizer in pediatrics
receiving HFNC therapy? What would the clinical response of aerosol administration be
in pediatrics receiving HFNC therapy?
Conclusions
Aerosol drug may be administered in pediatrics receiving HFNC therapy using
either jet nebulizer or pMDI. However, using pMDI, either with or without HFNC, is the
best option. In both devices, removing HFNC led to an increase in inhaled mass percent.
However, the benefit of increased aerosol delivery, when delivering medical aerosol by
mask, must be weighed against the risk of lung derecruitment when nasal prongs are
removed. Further studies are needed to determine the effect of aerosol delivery devices
and other breathing patterns on drug delivery to pediatrics receiving HFNC therapy.
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